Bristol Myers Squibb vs. COVID-19

We are working with researchers, the biotech community and the broader life sciences industry on ways we together can accelerate therapies for COVID-19.

Among other efforts, we have identified approximately 1,000 compounds in our discovery library that we’re making available to collaborators for screening for potential molecules to treat COVID-19.

We are evaluating certain medicines in our portfolio that could be included in near-term clinical trials with a focus on agents that may have an impact on the inflammatory immune response associated with COVID-19.

We are also participating in several cross-industry groups and public-private partnerships designed to coordinate industry response efforts, and thereby accelerate the development, manufacture, and delivery of vaccines, diagnostics, and treatments for COVID-19.

We have booked alternative means for moving our raw materials and products to our markets and clinical sites and, thanks to these efforts, we have not seen any disruption in our clinical or commercial supply chain due to the pandemic.

Bristol Myers Squibb and the Bristol Myers Squibb Foundation have contributed more than $22 million in financial support and needed products (e.g. PPE and medical equipment) to relief efforts in 40 countries.

The Bristol Myers Squibb Foundation has supported nearly 50 organizations in the U.S. and more than 150 organizations across the world, along with global organizations supporting those on the frontlines of the COVID-19 response.